# A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events

Source: https://onco.cc/trials/nct06500884/  
OnCo record `nct06500884` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Talquetamab in multiple myeloma, run by Janssen Research & Development, LLC, now recruiting.

## Summary

A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events is a phase 2 interventional study registered as NCT06500884 by Janssen Research & Development, LLC, with 210 participants planned, started 2024-08-26 and due to reach its primary completion in 2030-05-30. Interventions recorded: Talquetamab, Prophylaxis A, Prophylaxis B, Prophylaxis C, Prophylaxis D. Conditions listed: Multiple Myeloma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06500884
- Phase: 2
- Setting: A Phase 2, Open-label, Randomized Study to Evaluate GPRC5D-related Oral Events
- Sponsor: Janssen Research & Development, LLC
- Enrolled: 210

## Sources

- ClinicalTrials.gov NCT06500884: https://clinicaltrials.gov/study/NCT06500884

## Connected records

- cancers: [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/)
- drugs: [Talquetamab](https://onco.cc/drugs/talquetamab/)
- companies: [Johnson & Johnson](https://onco.cc/companies/johnson-johnson/)

---
JSON: https://onco.cc/api/v1/entities/nct06500884.json